GlassScriptPhysician profile
Tamara A Pride
NPI 1649494691
$18,386.00
in general payments reported to CMS, 2019-2025
31 companies · $3,437 in 2025
The $3,437 reported for 2025 was more than what 97% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,973 · 2022: $6,205 · 2023: $3,038 · 2024: $2,733 · 2025: $3,437.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,767 · Consulting Fee: $1,275 · Education: $166.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,767.25 |
| Consulting Fee | $1,275.00 |
| Education | $165.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $3,716.25 | 2021-2025 | Ilumya, Winlevi |
| Abbvie INC. | $3,254.73 | 2021-2025 | |
| Incyte Corporation | $1,571.62 | 2021-2025 | Opzelura |
| Mayne Pharma Commercial LLC | $1,326.37 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $1,121.92 | 2021-2025 | |
| Janssen Biotech, INC. | $1,073.55 | 2021-2025 | Tremfya, Simponi Aria, Simponi |
| Lilly USA, LLC | $1,029.41 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Epi Health, LLC | $955.35 | 2021-2022 | |
| Amgen INC. | $686.90 | 2021-2025 | Otezla, Otezla |
| Regeneron Healthcare Solutions, INC. | $576.89 | 2021-2025 | Dupixent |
| Genzyme Corporation | $478.90 | 2021-2025 | |
| Ucb, INC. | $317.87 | 2021-2024 | Bimzelx, Cimzia |
| Prugen, INC. Pharmaceuticals | $315.00 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $276.18 | 2023-2024 | Sotyktu |
| Dermavant Sciences, INC. | $240.83 | 2023-2024 | Vtama |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $237.90 | 2023-2025 | Zoryve |
| Pfizer INC. | $226.36 | 2021-2024 | |
| Vyne Pharmaceuticals INC. | $203.85 | 2021 | |
| Almirall LLC | $141.91 | 2021-2023 | Seysara |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $104.20 | 2021-2024 | Cabtreo |
| Biofrontera INC. | $91.74 | 2022-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Leo Pharma INC. | $73.86 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $72.00 | 2021 | |
| Organon LLC | $58.47 | 2025 | Vtama |
| Allergan, INC. | $48.48 | 2021-2022 | |
| Dermira, INC. | $46.08 | 2021 | |
| Galderma Laboratories, L.P. | $41.60 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.36 | 2023-2024 | Cyltezo |
| Verrica Pharmaceuticals INC. | $26.39 | 2025 | Ycanth |
| Krystal Biotech INC | $20.14 | 2024 | Vyjuvek |
| Organogenesis INC. | $14.89 | 2023 | Puraply |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tamara Pride listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.